Different Response to Roxadustat Treatment for Anemia Between Patients Undergoing Hemodialysis and Peritoneal Dialysis.

Different Response to Roxadustat Treatment for Anemia Between Patients Undergoing Hemodialysis and Peritoneal Dialysis. - Different Response to Roxadustat between HD and PD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039729

Enrollment

Registered

2020-03-06

Start date

2020-03-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End Stage Renal Disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: This study enrolled patients who were receiving maintenance HD or PD and were prescribed ESA.

Exclusion criteria

Exclusion criteria: Malignancy Blood disease that medical doctor considers not appropriate

Design outcomes

Primary

Measure	Time frame
The prespecified primary outcome was the average dose of roxadustat during weeks 23 through 27.	—

Secondary

Measure	Time frame
The secondary outcome was the prevalence of subject whose Hb levels increased 1.0 g/dL or 2.0 g/dL in first 4 weeks.	—

Countries

Japan

Contacts

Public ContactKeitaro Nishizawa

Japanese Red Cross Asahikawa Hospital Nephrology

nishizawa.1114@gmail.com0166228111

Outcome results